Inhibiting L1CAM Reverses Cisplatin Resistance of Triple Negative Breast Cancer Cells by Blocking AKT Signaling Pathway

References

• Pascua SM, McGahey GE, Ma N, Wang JJ, Digman MA. Caffeine and cisplatin effectively targets the metabolism of a triple-negative breast cancer cell line assessed via phasor-FLIM. IJMS. 2020;21(7):2443. doi:https://doi.org/10.3390/ijms21072443.
   Google Scholar
• Pattarawat P, Wallace S, Pfisterer B, Odoi A, Wang HR. Formulation of a triple combination gemcitabine plus romidepsin + cisplatin regimen to efficaciously and safely control triple-negative breast cancer tumor development. Cancer Chemother Pharmacol. 2020;85(1):141–152.
   PubMed Web of Science ®Google Scholar
• Baek DW, Park JY, Lee SJ, Chae YS. Impressive effect of cisplatin monotherapy on a patient with heavily pretreated triple-negative breast cancer with poor performance. Yeungnam Univ J Med. 2020;37(3):230–235.
   PubMedGoogle Scholar
• Haynes B, Gajan A, Nangia-Makker P, Shekhar MP. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence. Biochim Biophys Acta. 2020;1866(1):165561. doi:https://doi.org/10.1016/j.bbadis.2019.165561.
   PubMed Web of Science ®Google Scholar
• Baltes F, Pfeifer V, Silbermann K, Caspers J, Wantoch von Rekowski K, Schlesinger M, Bendas G. beta1-Integrin binding to collagen type 1 transmits breast cancer cells into chemoresistance by activating ABC efflux transporters. Biochim Biophys Acta. 2020;1867(5):118663.
   Web of Science ®Google Scholar
• Moos M, Tacke R, Scherer H, Teplow D, Fruh K, Schachner M. Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. Nature. 1988;334(6184):701–703.
   PubMed Web of Science ®Google Scholar
• Kong W, Wang X, Zhao J, Kang M, Xi N, Li S. A new frameshift mutation in L1CAM producing X-linked hydrocephalus. Mol Genet Genomic Med. 2020;8(1):e1031.
   PubMed Web of Science ®Google Scholar
• Li YT, Chen JS, Jian W, He YD, Li N, Xie YN, et al. L1CAM mutations in three fetuses diagnosed by medical exome sequencing. Taiwan J Obstet Gynecol. 2020;59(3):451–455.
   PubMed Web of Science ®Google Scholar
• Angiolini F, Cavallaro U. The pleiotropic role of L1CAM in tumor vasculature. IJMS. 2017;18(2):254. doi:https://doi.org/10.3390/ijms18020254.
   Google Scholar
• Giordano M, Cavallaro U. Different shades of L1CAM in the pathophysiology of cancer stem cells. JCM. 2020;9(5):1502. doi:https://doi.org/10.3390/jcm9051502.
   Google Scholar
• Ichikawa T, Okugawa Y, Toiyama Y, Tanaka K, Yin C, Kitajima T, et al. Clinical significance and biological role of L1 cell adhesion molecule in gastric cancer. Br J Cancer. 2019;121(12):1058–1068.
   PubMed Web of Science ®Google Scholar
• Tang T, Cheng Y, She Q, Jiang Y, Chen Y, Yang W, Li Y. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother. 2018;107:338–346. doi:https://doi.org/10.1016/j.biopha.2018.07.076.
   PubMed Web of Science ®Google Scholar
• Cho S, Lee TS, Song IH, Kim AR, Lee YJ, Kim H, et al. Combination of anti-L1 cell adhesion molecule antibody and gemcitabine or cisplatin improves the therapeutic response of intrahepatic cholangiocarcinoma. PLoS One. 2017;12(2):e0170078.
   PubMed Web of Science ®Google Scholar
• Yoon H, Min JK, Lee DG, Kim DG, Koh SS, Hong HJ. L1 cell adhesion molecule and epidermal growth factor receptor activation confer cisplatin resistance in intrahepatic cholangiocarcinoma cells. Cancer Lett. 2012;316(1):70–76.
   PubMed Web of Science ®Google Scholar
• Chen DL, Zeng ZL, Yang J, Ren C, Wang DS, Wu WJ, Xu RH. L1cam promotes tumor progression and metastasis and is an independent unfavorable prognostic factor in gastric cancer. J Hematol Oncol. 2013;6:43.
   PubMed Web of Science ®Google Scholar
• Jo DH, Lee K, Kim JH, Jun HO, Kim Y, Cho YL, et al. L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma. Oncotarget. 2017;8(9):15441–15452.
   PubMedGoogle Scholar
• Chiu WC, Lee YC, Su YH, Wang YY, Tsai CH, Hou YA, et al. The synthetic β-nitrostyrene derivative CYT-Rx20 inhibits esophageal tumor growth and metastasis via PI3K/AKT and STAT3 pathways. PLOS One. 2016;11(11):e0166453.
   PubMed Web of Science ®Google Scholar
• Cheriyan VT, Muthu M, Patel K, Sekhar S, Rajeswaran W, Larsen SD, et al. CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers. Oncotarget. 2016;7(45):73370–73388.
   PubMedGoogle Scholar
• Cataldo A, Romero-Cordoba S, Plantamura I, Cosentino G, Hidalgo-Miranda A, Tagliabue E, Iorio MV. MiR-302b as a combinatorial therapeutic approach to improve cisplatin chemotherapy efficacy in human triple-negative breast cancer. Cancers. 2020;12(8):2261. doi:https://doi.org/10.3390/cancers12082261.
   Web of Science ®Google Scholar
• Faltas BM, Prandi D, Tagawa ST, Molina AM, Nanus DM, Sternberg C, et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat Genet. 2016;48(12):1490–1499.
   PubMed Web of Science ®Google Scholar
• Sebens Muerkoster S, Werbing V, Sipos B, Debus MA, Witt M, Grossmann M, et al. Drug-induced expression of the cellular adhesion molecule L1CAM confers anti-apoptotic protection and chemoresistance in pancreatic ductal adenocarcinoma cells. Oncogene. 2007;26(19):2759–2768.
   PubMed Web of Science ®Google Scholar
• Roberts CM, Tran MA, Pitruzzello MC, Wen W, Loeza J, Dellinger TH, et al. TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. Sci Rep. 2016;6(1):37652. doi:https://doi.org/10.1038/srep37652.
   PubMedGoogle Scholar
• Stoeck A, Gast D, Sanderson MP, Issa Y, Gutwein P, Altevogt P. L1-CAM in a membrane-bound or soluble form augments protection from apoptosis in ovarian carcinoma cells. Gynecol Oncol. 2007;104(2):461–469.
   PubMed Web of Science ®Google Scholar
• Lee SB, Schramme A, Doberstein K, Dummer R, Abdel-Bakky MS, Keller S, et al. ADAM10 is upregulated in melanoma metastasis compared with primary melanoma. J Invest Dermatol. 2010;130(3):763–773.
   PubMed Web of Science ®Google Scholar
• Schafer H, Geismann C, Heneweer C, Egberts JH, Korniienko O, Kiefel H, et al. Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent. Carcinogenesis. 2012;33(1):84–93.
   PubMed Web of Science ®Google Scholar
• Togami K, Yamaguchi K, Tada H, Chono S. Assessment of transporter-mediated efflux of nintedanib using in vitro cell line models of idiopathic pulmonary fibrosis. Pharmazie. 2020;75(8):371–374.
   PubMed Web of Science ®Google Scholar
• Alraouji NN, Al-Mohanna FH, Ghebeh H, Arafah M, Almeer R, Al-Tweigeri T, Aboussekhra A. Tocilizumab potentiates cisplatin cytotoxicity and targets cancer stem cells in triple-negative breast cancer. Mol Carcinog. 2020;59(9):1041–1051. doi:https://doi.org/10.1002/mc.23234.
   PubMed Web of Science ®Google Scholar
• Lund K, Dembinski JL, Solberg N, Urbanucci A, Mills IG, Krauss S. Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment. PLoS One. 2015;10(4):e0123684.
   PubMed Web of Science ®Google Scholar
• Chen J, Gao F, Liu N. L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer. Exp Ther Med. 2018;15(3):2792–2797.
   PubMed Web of Science ®Google Scholar
• Wadhwa B, Paddar M, Khan S, Mir S, P AC, Grabowska AM, et al. AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity. Oncotarget. 2020;11(45):4178–4194.
   PubMedGoogle Scholar
• Tang H, Massi D, Hemmings BA, Mandala M, Hu Z, Wicki A, Xue G. AKT-ions with a TWIST between EMT and MET. Oncotarget. 2016;7(38):62767–62777.
   PubMedGoogle Scholar
• Paramanantham A, Kim MJ, Jung EJ, Kim HJ, Chang SH, Jung JM, et al. Anthocyanins isolated from Vitis coignetiae Pulliat enhances cisplatin sensitivity in MCF-7 human breast cancer cells through inhibition of Akt and NF-kappaB activation. Molecules. 2020;25(16):3623. doi:https://doi.org/10.3390/molecules25163623.
   Web of Science ®Google Scholar
• Hahne JC, Honig A, Meyer SR, Gambaryan S, Walter U, Wischhusen J, et al. Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitro. Oncol Rep. 2012;28(6):2023–2028.
   PubMed Web of Science ®Google Scholar
• Im E, Yeo C, Lee EO. Luteolin induces caspase-dependent apoptosis via inhibiting the AKT/osteopontin pathway in human hepatocellular carcinoma SK-Hep-1 cells. Life Sci. 2018;209:259–266.
   PubMed Web of Science ®Google Scholar
• Zhu M, Ying J, Lin C, Wang Y, Huang K, Zhou Y, Teng H. Baicalin induces apoptotic death of human chondrosarcoma cells through mitochondrial dysfunction and downregulation of the PI3K/Akt/mTOR pathway. Planta Med. 2019;85(5):360–369.
   PubMed Web of Science ®Google Scholar